|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US6409990||CARDINAL HEALTH 414||Macromolecular carrier for drug and diagnostic agent delivery|| |
(1 year, 7 months from now)
|US9439985||CARDINAL HEALTH 414||Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran|| |
(5 years from now)
Lymphoseek Kit is owned by Cardinal Health 414.
Lymphoseek Kit contains Technetium Tc-99M Tilmanocept.
Lymphoseek Kit has a total of 2 drug patents out of which 0 drug patents have expired.
Lymphoseek Kit was authorised for market use on 13 March, 2013.
Lymphoseek Kit is available in injectable;injection dosage forms.
The generics of Lymphoseek Kit are possible to be released after 30 January, 2029.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Patient Population (NPP)||May 19, 2024|
Market Authorisation Date: 13 March, 2013
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic